# OnCo record idea-net-antagonist-ligands (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-net-antagonist-ligands/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-net-antagonist-ligands" ;
  schema:name "SSTR antagonist radioligands to increase tumour dose"@en ;
  schema:description "Radioligand therapy for neuroendocrine tumours built on somatostatin receptor antagonists rather than the agonists used today: antagonists bind the receptor in every state and are not internalised, so they occupy several times more sites per cell and deliver more radiation per dose. The test is a randomised phase 2 against agonist lutetium therapy."@en ;
  schema:url <https://onco.cc/ideas/idea-net-antagonist-ligands/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://doi.org/10.1158/1078-0432.CCR-19-1026> ;
  onco:cancers <https://onco.cc/cancers/neuroendocrine/> ;
  onco:technologies <https://onco.cc/technologies/prrt/> ;
  onco:targets <https://onco.cc/targets/sstr2/> ;
  onco:trials <https://onco.cc/trials/alphamedix-02/>, <https://onco.cc/trials/compete/>, <https://onco.cc/trials/nct04919226/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-reidy-lagunes-clin-cancer-res/> .